Idéal Investisseur Connexion Connexion
Français English
CAC 40 : Market closed
7 927,75 pts
-1.89%


Last updated : 20/11/2026 - 17h35 (last close)
Last close data
🏠 Home   ➤    Stock news

Transgene: Positive Preclinical Results for its TG-MVA Vaccine Against Monkeypox

On Thursday in Strasbourg, Transgene presented encouraging preclinical results for TG-MVA, its next-generation vaccine candidate against monkeypox and smallpox. The program aims to diversify the global supply in response to current production capacity deficits and to leverage investments already made in the cellular manufacturing platform.


Transgene: Positive Preclinical Results for its TG-MVA Vaccine Against Monkeypox

A Cellular Manufacturing Platform to Enhance Global Health Security

TG-MVA is a vaccine candidate based on Modified Vaccinia Ankara (MVA) designed to address supply chain and production challenges currently concentrated among a limited number of manufacturers. The candidate utilizes an innovative manufacturing process on avian cell lines, capable of replacing the traditional method using chicken embryo fibroblasts (CEF). This approach allows for scalable and reproducible production, thus circumventing known industrial limitations.

Transgene positions this initiative in a context of growing concerns about biosecurity and pandemic preparedness in Europe and the United States, combined with a substantial gap in vaccine capacity. The group emphasizes that these production innovations, initially developed for its Myvac platform, can be applied to the prevention of monkeypox and other orthopoxviruses.

Preclinical Results Comparable to Approved Reference Vaccines

TG-MVA was evaluated in murine and non-human primate models. The candidate demonstrated efficacy, immunogenicity, and a safety profile comparable to the currently approved MVA reference vaccine. The data show identical survival rates (100% in mice, 87% in primates), protection against disease severity including reduced lesion formation, and control of viral load. Immune responses include a level of neutralizing antibodies comparable to that induced by the reference vaccine, as well as broad humoral and cellular responses, including T-cell immunity, across all tested models. The safety profile proved comparable, with only mild and transient reactogenicity.

These data support the candidate's potential to address future vaccine supply gaps for monkeypox and smallpox.

Accelerating Towards Clinical Development

Transgene plans to rapidly advance TG-MVA towards clinical development, while confirming its ongoing strategic priority on its Myvac platform for individualized therapeutic vaccines and reiterating its financial visibility through early 2028. The data presentation was made on Thursday during an oral presentation at the World Congress on Infectious Diseases (WCID) 2026 in Strasbourg, by Nathalie Silvestre, head of the Vectorology Laboratory at Transgene.

Free · Every morning
Technical market signals, before the opening bell.
Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.
✓ Before 9 AM every morning ✓ Euronext data ✓ AI-powered analysis


Sector Pharmacie et biotechnologies › Biotechnologies


Context

Period
  • Period: 9M 2026
Guidance from the release
  • Under current plans, the company has sufficient cash to ensure financial visibility until early 2028
Risks mentioned
  • L'activité repose sur le succès de essais cliniques en phase 1/2 pour TG4050 et TG4070, avec résultats finaux attendus fin Q1 2028
  • La dépendance à l'égard du crédit d'impôt recherche (CIR) : €3,9 M sur €4,3 M d'operating income, soit 91% de ce résultat
  • Consommation de trésorerie continue : €29,5 M en 9 mois 2026, limitant la visibilité au-delà de début 2028
Opportunities identified
  • Publication positive de TG4050 dans Nature Communications confirmant 100% DFS après 3+ ans, validant le modèle clinique
  • Expansion de la plateforme myvac® avec lancement de TG4070 en phase 1 combinée nivolumab dans le poumon (NSCLC)
  • Capacités de production en phase 3 prêtes fin 2027 et clarté financière jusqu'à début 2028 pour financer les développements

The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.

Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.

Advertisement
Every morning
Technical market signals,
before the opening bell.
CAC 40 · SBF 120 · Signals · Analysts
🤖
Today's edition — pre-market
CAC 40
7 702
-0,87%
SBF 120
5 827
-0,87%
📈 Bullish signals
+5,2%
+1,8%
+0,9%
📉 Bearish signals
-14%
-5,7%
🔄 Analyst opinions
▲ 35 €
▼ 80 €
Sign up to see everything →
Before 9 AM every morning
Euronext data
AI-powered analysis





BOURSE · Chaque matin
La synthèse bourse,
avant l'ouverture.
Notre moteur analyse chaque nuit le CAC 40 et le SBF 120. Ce qui mérite attention remonte directement dans votre boîte mail. Gratuit.
✓ Avant 9h00 ✓ 1000+ inscrits ✓ 100% gratuit
Gratuit · chaque matin
Ne ratez plus rien sur vos actions
La tendance derrière les cours sur les valeurs Euronext, chaque matin avant 9h.
tendance · 6 séances
📈les valeurs en mouvement, sur la durée
🎯les objectifs d'analystes qui évoluent
📰les actualités qui font bouger les cours